Prevention and Decolonization of Multidrug-resistant Bacteria With Probiotics

Probiotics Clinical Trial

Official title:

Prevention and Decolonization of Carbapenemase-producing Enterobacteriaceae With Probiotics

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03967301
• Other study ID #: 3738
• Status: Not yet recruiting
• Phase: N/A
• Start date: October 2019
• Est. completion date: December 2019

Study information

• Verified date: August 2019
• Source: Hospital Italiano de Buenos Aires
• Contact: Maria I Staneloni, MD
• Phone: 1536670333.
• Email: maria.staneloni[@]hospitalitaliano.org.ar
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study explores the effect of probiotic administration to decrease colonization by Carbapenem resistant Enterobacteriaceae (CRE) in at-risk populations. Colonized patients will be randomized to receive probiotics or placebo for 14 days and reevaluated for colonization in follow up.

Description:

The use of antibiotics is known to have significant effects on the intestinal microbiota. Studies have linked this alteration with the risk of colonization and / or infection by Carbapenem resistant Enterobacteriaceae (CRE) and / or Clostridium difficile (Cd). The impact of these microorganisms has been demonstrated, with mortality rates in inpatients of around 30-50% for patients infected with CRE and 10% in Cd. It is necessary to implement mechanisms to contain dissemination and decrease colonization, in order to prevent infections caused by such agents.

Probiotics are foods consisting of live microorganisms and could restore the balance of the microbiota and avoid colonization by multi-resistant germs. Systematic reviews have shown a protective effect of probiotics for Cd. Studies on the effect on CRE are scarce and have been related mostly to prevention of colonization. Among the probiotics obtained by bacterial fermentation technology and already available in pharmacopoeia we have Bioflora ®. The objective of this trial is to explore the effect of probiotic consumption to decrease the duration of the colonization by CRE by comparing the percentage of patients colonized with CRE after the administration of probiotics and in the untreated group.

Methodology: Randomized clinical trial, single center. Known CRE colonized patients will be randomized to consume probiotics for 14 days or placebo. Then the colonization will be evaluated by means of anal swabs as indicated by the hospital standards with a follow up of 12 weeks from the initial intervention.

If the patient is discharged, home follow-up will be scheduled to supervise the intake of the dietary supplement and the control swabs.

The expected impact is to accelerate the process of decolonization of multi-resistant germs through the administration of probiotics leading to a shorter contact isolation time in and reducing the risk of complications in CRE colonized patients.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 228
• Est. completion date: December 2019
• Est. primary completion date: December 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• CRE- colonized patients

• adult patients in hospital (over 18 years old)

• Part of the HIBA health care plan

• CRE positive rectal swab or stool in the last 14 days

Exclusion criteria:

• Enteral route enabled (oral, nasogastric tube, gastrostomy or jejunostomy)

• Refusal to participate in the study

• Not available for weekly checks, minimum up to 12 weeks from enrollment

• Clostridium difficile active infection concomitant with CRE swab in a 14-day period days

• Neutropenia G3 or greater (less than 1000 neutrophils at the time of enrollment).

• Severe immunosuppressed at the time of recruitment according to the CDC definition (patients transplanted, HIV with CD4 <200, congenital immunodeficiencies, leukemias, lymphomas, cancer disseminated, current chemotherapy or radiotherapy, treatment with corticoids high dose:prednisone 20 mg / d> 2 weeks or immunosuppressive drugs).

• Patient with valvular prostheses

• Imminent death

• Fistula or dehiscence of the gastrointestinal tract

• Acute pancreatitis

• Patient of critical units in ileus and / or with high requirement of vasopressors (noradrenaline equal to or greater than 0.5 gammas) at the time of recruitment

Related Conditions & MeSH terms

• Enterobacteriaceae Infections
• Probiotics

Intervention

Dietary Supplement:
• Probiotic
Intervention: defined as probiotic consumption
• Placebo
Placebo consumption. The placebo will be provided by the company that produces the probiotic.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Hospital Italiano de Buenos Aires

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	presence of CRE in anal swab or stool culture in follow-up control:	CRE anal swab positive upon discharge, therapeutic adjustment or in-hospital death.; ? Date of swab, therapeutic adjustment or in-hospital death.; and within a month : ? Control CRE swab per month for KPC: Categorical binomial: Positive / Negative. Will be performed 30 days after enrollment and weekly for 8 weeks if positive. It will be considered negative when the patient as three consecutive negative swabs separated by a week. It will be persistently positive when during this period of follow-up at least one of the swabs is positive, total follow-up 12 weeks	12 weeks
Secondary	positive for clostridium difficile diarrhea	If a patient develops diarrhea at some point during hospitalization, screening for Cd will be performed at the attending phisician´s discretion; If the patient has diarrhea with a positive Cd toxin and is receiving probiotic he/she should leave the study and the data for CRE will be evaluated with the last available swab at the time of the exit event (positive for clostridium difficile diarrhea).	12 weeks